Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction.

Acta Biomaterialia
Kelly R RhodesJordan J Green

Abstract

Regulatory T cell (Treg)-based therapeutics are receiving increased attention for their potential to treat autoimmune disease and prevent transplant rejection. Adoptively transferred Tregs have shown promise in early clinical trials, but cell-based therapies are expensive and complex to implement, and "off-the-shelf" alternatives are needed. Here, we investigate the potential of artificial antigen presenting cells (aAPCs) fabricated from a blend of negatively charged biodegradable polymer (poly(lactic-co-glycolic acid), PLGA) and cationic biodegradable polymer (poly(beta-amino ester), PBAE) with incorporation of extracellular protein signals 1 and 2 and a soluble released signal 3 to convert naïve T cells to induced Foxp3+ Treg-like suppressor cells (iTregs) both in vitro and in vivo in a biomimetic manner. The addition of PBAE to the aAPC core increased the conjugation efficiency of signal proteins to the particle surface and resulted in enhanced ability to bind to naïve T cells and induce iTregs with potent suppressive function. Furthermore, PLGA/PBAE tolerogenic aAPCs (TolAPCs) supported the loading and sustained release of signal 3 cytokine TGF-β. A single dose of TolAPCs administered intravenously to C57BL/6 J mice resulte...Continue Reading

References

Jul 23, 2003·The Journal of Experimental Medicine·Sayuri YamazakiRalph M Steinman
Apr 3, 2004·Nature Biotechnology·Jiyun V KimMichel Sadelain
Jun 9, 2004·The Journal of Experimental Medicine·Qizhi TangJeffrey A Bluestone
Jun 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Steven R LittleRobert Langer
Mar 22, 2006·Proceedings of the National Academy of Sciences of the United States of America·Julie A Champion, Samir Mitragotri
Feb 15, 2007·PLoS Biology·Stefan FloessJochen Huehn
May 16, 2007·The Journal of Experimental Medicine·Silvia DeaglioSimon C Robson
May 22, 2008·European Journal of Immunology·Julia K PolanskyJochen Huehn
Jun 21, 2008·Nature Reviews. Immunology·Dario A A VignaliCreg J Workman
Dec 31, 2008·Nature Reviews. Immunology·Jochen HuehnAlf Hamann
Jun 30, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Piotr TrzonkowskiAndrzej Hellmann
Apr 29, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qian ChenEthan M Shevach
Aug 23, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·S Alice Long, Jane H Buckner
Dec 14, 2011·European Journal of Immunology·Alicia N McMurchy, Megan K Levings
Apr 23, 2013·Trends in Molecular Medicine·Luca AntonioliGyörgy Haskó
Oct 12, 2013·Nano Letters·Jovana MaticJoachim P Spatz
Nov 5, 2014·Molecular Therapy. Methods & Clinical Development·Debalina SarkarRoland W Herzog
Nov 27, 2015·Science Translational Medicine·Jeffrey A BluestoneQizhi Tang
Mar 5, 2017·Immunological Reviews·Bertrand AllardJohn Stagg
May 26, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Mateusz GliwińskiPiotr Trzonkowski
Jan 16, 2018·Nature Biotechnology·Alexander S CheungDavid J Mooney
Mar 12, 2018·Molecular Immunology·Kelly R Rhodes, Jordan J Green
Nov 13, 2018·Biomaterials Science·Elana Ben-AkivaJordan J Green

❮ Previous
Next ❯

Citations

Mar 31, 2021·Current Opinion in Organ Transplantation·Hailey M ShepherdDaniel Kreisel
Dec 20, 2021·Seminars in Immunology·Savannah E Est-WitteJonathan P Schneck

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.